Navigation Links
Study identifies potential 'safe period' for hormone replacement use
Date:2/2/2009

A new study makes important new findings on the role of hormone use on the risk of breast cancer, confirming that the use of estrogen plus progesterone increases the risk of both ductal and lobular breast cancer far more than estrogen-only; suggesting a two-year "safe" period for the use of estrogen and progesterone; and finding that the increased risk for ductal cancers observed in long-term past users of hormone replacement therapy drops off substantially two years after hormone use is stopped. The study appears in CANCER, a peer-reviewed journal of the American Cancer Society.

Previous studies have shown that hormone replacement therapy after menopause increases the risk of breast cancer and that use of a regimen that includes both estrogen and progesterone is more detrimental for the breast than the use of estrogen alone. But more data from large prospective studies are needed to fully characterize the impact of exogenous hormones on breast cancer incidence by type of hormone preparation and histology of the cancer.

To investigate the association in more detail, American Cancer Society epidemiologists led by Eugenia E. Calle, PhD, did a prospective study of 68,369 postmenopausal women who were cancer-free at baseline in 1992. They examined the use of estrogen-only and estrogen and progesterone in current and former users of varying duration, and the subsequent risk of developing invasive ductal and lobular carcinoma of the breast. They also looked at whether the risk for each type of breast cancer and each type of hormone regimen varied by body mass index (BMI), stage of disease at diagnosis, and estrogen receptor (ER) and progesterone receptor (PR) status. For the present study, the follow-up period ended on June 30, 2005.

They confirmed the findings from previous work that estrogen and progesterone increases the risk of both ductal and lobular breast cancer far more estrogen alone. They also found the risk associated with use of estrogen and progesterone increases significantly and substantially within three years of beginning hormone use. The data showed no increased risk for women who used estrogen and progesterone for less than two years, potentially identifying a "safe" period for estrogen and progesterone use.

The study also found no increased risk of breast cancer in women who had stopped using estrogen and progesterone two or more years ago, suggesting a window of two to three years for the risks of estrogen and progesterone both to become apparent after initial use and to diminish after cessation. Few estimates of risk within two to three years of initiation and cessation are available, so these findings need replication in other large studies.

The study found the use of estrogen and progesterone was associated with a doubling of risk of lobular cancer after three years of use, and a doubling of risk of ductal cancer with 10 years of use. Estrogen-only use was not associated with increased risk of ductal cancer, even after 20 years of use, but was associated with a 50 percent increase in risk of lobular cancer after 10 years of use.


'/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Related medicine news :

1. Penn study finds link between Parkinsons disease genes and manganese poisoning
2. Study suggests that inflammation may be the link between extreme sleep durations and poor health
3. Study finds genetic link between sleep disorders and depression in young children
4. Stanford study prevents pancreatic tumor growth in mice by inhibiting key protein
5. Study of Iraq veterans traumatic brain injuries to be conducted by UB researchers
6. Study confirms persistence of diversity problems in academic medicine
7. Oncogene inhibits tumor suppressor to promote cancer: Study links B-RAF and LKB1
8. Perceptions and experiences of homeless youth vary by race, UCSF study shows
9. New Study: Protein in the Morning Helps Dieters Stay on Track and Keep Weight Off
10. New study explores the relationship between preterm birth and autism spectrum disorder
11. Study finds preemies more likely to score positive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... Guide to ... , No matter on which side of the Atlantic devicemakers do business, ... regulations they have to follow. , In addition to the full text of the ...
(Date:6/28/2017)... ... June 28, 2017 , ... Anyone with a remote control has seen the never-ending twists ... you the flipper will get rich in no time. But what about the buyers ... get for the buyer of a flipped house. An email recently sent to Gary ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... David B. Sosin, a founding ... Illinois, took over the post of 2nd Vice President for the Illinois State Bar ... installed as the ISBA’s 3rd Vice President in 2016 following a state-wide election and served ...
(Date:6/28/2017)... ... ... American Farmer proudly announces the participation of Pure Line Seeds, Inc (Pure ... broadcast fourth quarter 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , Founded ... As demand grew, the small company located in Moscow, Idaho extended its sales from ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... ZEON) is pleased to announce that a two year study conducted by the ... Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... CALABASAS, Calif. , June 14, 2017 ... with the City of Fremont ... chain of the bio-pharma industry in California ... sharing technology, enabling executive networking, and fostering workforce development. ... the development and growth of start-ups, as well as ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company (NYSE: ... three Phase 3 studies of galcanezumab, an investigational treatment ... late-breaking data on several key secondary endpoints for galcanezumab ... from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be ... scientific meeting in Boston . ...
(Date:6/8/2017)... MAITLAND, Fla. , June 8, 2017  Less ... ransomware attack that hit more than 200,000 companies, including hospital ... is being heralded as one of the largest online ... technology in the healthcare market, it is imperative that ... can protect their data from this — and many ...
Breaking Medicine Technology: